Ausgewählte Publiktionen 2017

  • Bartkowiak D, Thamm R, Bottke D, Siegmann A, Böhmer D, Budach V, Wiegel T. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncol. 2017 Aug 17:1-6. doi: 10.1080/0284186X.2017.1364869. [Epub ahead of print]

  • Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A. Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. Eur Urol. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026. [Epub ahead of print]

  • Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017 Jul 27. pii: S0302-2838(17)30535-3. doi: 10.1016/j.eururo.2017.06.035. [Epub ahead of print]

  • Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017 Jun 24. pii: S0302-2838(17)30497-9. doi: 10.1016/j.eururo.2017.06.002. [Epub ahead of print]

  • Budäus L, Schiffmann J, Graefen M, Huland H, Tennstedt P, Siegmann A, Böhmer D, Budach V, Bartkowiak D, Wiegel T. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate. Strahlenther Onkol. 2017 May 3. doi: 10.1007/s00066-017-1140-y. [Epub ahead of print]

  • Wollschläger D, Merzenich H, Schwentner L, Janni W, Wiegel T, Bartkowiak D, Wöckel A, Schmidt M, Schmidberger H, Blettner M. Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study). Breast Cancer Res Treat. 2017 Jun;163(3):595-604

  • Bottke D, Bolenz C, Ott S, Cebulla A, Wiegel T. [When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?] Urologe A. 2017 May;56(5):579-584.

  • MacLennan S, Williamson PR, Bekema H, Campbell M, Ramsay C, N'Dow J, MacLennan S, Vale L, Dahm P, Mottet N, Lam T; COMPACTERS study group., Abel P, Ahmed HU, Akehurst G, Almquist R, Beck K, Budd D, Canfield S, Catto J, Cornford P, Cross W, Ewen A, Grant J, Heer R, Hurst D, Jones R, Kockelbergh R, Mackie A, MacDonald G, McNeill A, Mason M, McClinton S, McLaren D, Mostafid H, Pearce I, Pennet L, Royle J, Schreuder H, Stewart GD, van der Poel H, Wardlaw K, Wiegel T.  A core outcome set for localised prostate cancer effectiveness trials. BJU Int. 2017 Mar 27. doi: 10.1111/bju.13854. [Epub ahead of print]

  • Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RC, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30115-X. doi: 10.1016/j.eururo.2017.02.026. [Epub ahead of print] Review.

  • Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, Friebe-Hoffmann U, Bullinger L, Möller P, Wiegel T. Response Evaluation in Head and Neck Oncology: Definition and Prediction. ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2):14-23.

  • Fossati N, Willemse PM, van den Bergh RC, Van den Broeck T, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. 2017 Jul;72(1):84-109.

  • Wollschläger D, Karle H, Stockinger M, Bartkowiak D, Bührdel S, Merzenich H, Wiegel T, Schmidberger H, Blettner M. Predicting Heart Dose in Breast Cancer Patients Who Received 3D Conformal Radiation Therapy. Health Phys. 2017 Jan;112(1):1-10.

  • Merzenich H, Bartkowiak D, Schmidberger H, Schmidt M, Schwentner L, Wiegel T, Woeckel A, Wollschläger D, Blettner M. 3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study). Breast Cancer Res Treat. 2017 Jan;161(1):143-152.

  • Höcht S, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Hölscher T, Martin T, Sedlmayer F, Wenz F, Zips D, Wiegel T. Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2017 Jan;193(1):1-12

  • Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017 Apr;71(4):630-642.

  • Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618-629

  • Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Chiorda BN, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. Eur Urol. 2017 Jun;71(6):886-893

Ausgewählte Publikationen 2016

  • van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol. 2016 May;69(5):802-20.

  • Fiorino C, Broggi S, Fossati N, Cozzarini C, Goldner G, Wiegel T, Hinkelbein W, Karnes RJ, Boorjian SA, Haustermans K, Joniau S, Palorini F, Shariat S, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, Briganti A. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):333-40

  • Bartkowiak D. AUO. Adjuvante Strahlentherapie nach radikaler Prostatektomie. Aktuelle Urol. 2016 Feb;47(1):22-4.

  • Ebner F, Schramm A, Bottke D, Friedl TW, Wiegel T, Fink V, Lato K, Bekes I, Janni W, de Gregorio N. Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost. Arch Gynecol Obstet. 2016 Oct;294(4):861-6

  • Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S. Quality assessment in prostate cancer centers certified by the German Cancer Society. World J Urol. 2016 May;34(5):665-72.

  • Böhmer D, Wirth M, Miller K, Budach V, Heidenreich A, Wiegel T. Radiotherapy and Hormone Treatment in Prostate Cancer. Dtsch Arztebl Int. 2016 Apr 8;113(14):235-41

  • Bottke D, Bartkowiak D, Bolenz C, Wiegel T. [Radiotherapy in node-positive prostate cancer]. Urologe A. 2016 Mar;55(3):345-9.

  • Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol. 2016 Apr;69(4):728-33.

  • Breul J, Wiegel T. Radiotherapy vs. radical surgery. Urologe A. 2016 Mar;55(3):311-2.

  • Ohlmann CH, Stöckle M, Albers P, Schmidberger H, Härter M, Kristiansen G, Martus P, Wellek S, Bussar-Maatz R, Wiegel T. PREFERE - Study on the rise. Urologe A. 2016 Mar;55(3):313-7.

  • Wollschläger D, Karle H, Stockinger M, Bartkowiak D, Bührdel S, Merzenich H, Wiegel T, Blettner M, Schmidberger H. Radiation dose distribution in functional heart regions from tangential breast cancer radiotherapy. Radiother Oncol. 2016 Apr;119(1):65-70.

  • Bartkowiak D, Bottke D, Thamm R, Siegmann A, Hinkelbein W, Wiegel T. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Radiother Oncol. 2016 Jan;118(1):131-5.

Ausgewählte Publikationen 2015

  • van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.Eur Urol. 2015 Dec 12. pii: S0302-2838(15)01178-1. doi: 10.1016/j.eururo.2015.11.023. [Epub ahead of print]

  • Rexer H, Bartkowiak D. Adjuvant radiotherapy in lymph-node-positive prostate cancer with low tumor burden after radical prostatectomy : Multicenter randomized phase III trial on the effect of adjuvant radio therapy in patients with prostate cancer with or without positive margins after radical prostatectomy (RP) and lymph node metastasis with low tumor burden (micrometastases, ≤ 2 lymph node macrometastases). ART-2 trial AP 61/11 of the AUO. Urologe A. 2015 Jun;54(6):871-4. doi: 10.1007/s00120-015-3824-1.

  • Bossi A, Wiegel T, Roach M. Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine. Eur Urol. 2015 Nov;68(5):775-6.

  • Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.

  • ICECaP Working Group. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015 Sep 25;107(12).

  • Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A: Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol. 2015 Oct 20. [Epub ahead of print]

  • Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S. Quality assessment in prostate cancer centers certified by the German Cancer Society. World J Urol. 2015 Sep 21. [Epub ahead of print]

  • Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, Ganzer R, Wieland W, Eder F, Hofstädter F, Schilling D, Sievert KD, Stenzl A, Scharpf M, Fend F, Vom Dorp F, Rübben H, Kurt Werner S, Porres-Knoblauch D, Heidenreich A, Hangarter B, Knüchel-Clarke R, Rogenhofer M, Wullich B, Hartmann A, Comploj E, Pycha A, Hanspeter E, Pehrke D, Sauter G, Graefen M, Gratzke C, Stief C, Wiegel T, Haese A. Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin - A multicenter study. Radiother Oncol. 2015 Jul;116(1):119-24

  • Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A. Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43.

  • Sänger S, Wiegel T, Stöckle M, Härter M, Bergelt C.  [Development of patient education materials for the "German Prostate Cancer Trial PREFERE"]. Z Evid Fortbild Qual Gesundhwes. 2015;109(1):28-39.

  • Bartkowiak D, Schrader AJ, Wiegel T. [Adjuvant vs. salvage radiotherapy after radical prostatectomy]. Aktuelle Urol. 2015 Jan;46(1):52-8.

  • Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94.

  • Wiegel T, Stöckle M, Bartkowiak D. PREFEREnce-based randomized evaluation of treatment modalities in low or early intermediate-risk prostate cancer. Eur Urol. 2015 Jan;67(1):1-2.

  • Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol. 2015 Mar;67(3):460-7.

  • Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B. Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. Eur Urol. 2015 May;67(5):904-12.

  • Koontz BF, Bossi A, Cozzarini C, Wiegel T, D'Amico A. A Systematic Review of Hypofractionation for Primary Management of Prostate Cancer. Eur Urol. 2015 Oct;68(4):683-91.

Ausgewählte Publikationen 2014

  • Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium, and the CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1100-8.

  • Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; on behalf of the ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8

  • Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K. Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96-02/AUO AP 09/95 Trial. Eur Urol. 2014 Aug;66(2):243-50.

  • Lohm G, Lütcke J, Jamil B, Höcht S, Neumann K, Hinkelbein W, Wiegel T, Bottke D. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey. Strahlenther Onkol. 2014 Aug;190(8):727-31.

  • Wöckel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R, Wischnewsky M, Schwentner L; BRENDA study group. The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects. Ann Oncol. 2014 Mar;25(3):628-32.

  • Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol. 2014 Feb;65(2):467-79.

  • Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013. Eur Urol. 2014 Jan;65(1):124-37.

  • Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ: Early Salvage Radiotherapy Following Radical Prostatectomy. Eur Urol. 2014 Jun;65(6):1034-43.

Ausgewählte Publikationen 2013

  • Briganti A, Joniau S, Gandaglia G, Cozzarini C, Sun M, Tombal B, Haustermans K, Hinkelbein W, Shariat SF, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):960-7.

  • Kristiansen G, Stöckle M, Albers P, Schmidberger H, Martus P, Wellek S, Härter M, Bussar-Maatz R, Wiegel T. [The importance of pathology in the German prostate cancer study PREFERE]. Pathologe. 2013 Sep;34(5):449-62.

  • Baumunk D, Reunkoff R, Kushner J, Baumunk A, Kempkensteffen C, Steiner U, Weikert S, Moser L, Schrader M, Höcht S, Wiegel T, Miller K, Schostak M: Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin. BMC Med Inform Decis Mak. 2013 Aug 5;13:83.

  • Matuschek C, Bölke E, Belka C, Ganswindt U, Henke M, Stegmaier P, Bamberg M, Welz S, Debus J, Gioules A, Voigt A, Volk G, Ohmann C, Wiegel T, Budach V, Stuschke M, Schipper J, Gerber PA, Budach W: Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2013 Aug;189(8):625-631.

  • Fietkau R, Lewitzki V, Kuhnt T, Hölscher T, Hess CF, Berger B, Wiegel T, Rödel C, Niewald M, Hermann RM, Lubgan D: A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: Results of a randomized, controlled, multicenter trial. Cancer. 2013 Sep 15;119(18):3343-53.

  • Wiegel T, Albers P, Bussar-Maatz R, Gottberg A, Härter M, Kieser M, Kristiansen G, Nettekoven G, Martus P, Schmidberger H, Wellek S, Stöckle M. [PREFERE - the German prostatic cancer study : Questions and claims surrounding study initiation in January 2013]. Urologe A. 2013 Apr;52(4):576-9.
  • Bottke D, Golz R, Störkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T. Phase 3 Study of Adjuvant Radiotherapy Versus Wait and See in pT3 Prostate Cancer: Impact of Pathology Review on Analysis. Eur Urol. 2013 Aug;64(2):193-8.
  • Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V; Panel Members. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol. 2013 May;24(5):1141-62.
  • Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, Bergqvist PB, Khoo V: Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide. Clin Oncol (R Coll Radiol). 2013 Mar;25(3):190-6.
  • Kornmann M, Staib L, Wiegel T, Kron M, Henne-Bruns D, Link KH, Formentini A; Study Group Oncology of Gastrointestinal Tumors (FOGT): Long-Term Results of 2 Adjuvant Trials Reveal Differences in Chemosensitivity and the Pattern of Metastases Between Colon Cancer and Rectal Cancer. Clin Colorectal Cancer. 2013 Mar;12(1):54-61.
  • Lohm G, Bottke D, Jamil B, Miller K, Neumann K, Bartkowiak D, Hinkelbein W, Wiegel T: Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results. World J Urol. 2013 Apr;31(2):423-8.

  • Bartkowiak D, Bottke D, Wiegel T. Adjuvant radiotherapy or early salvage radiotherapy in pT3R0 or pT3R1 prostate cancer. Curr Opin Urol. 2013 Jul;23(4):360-5.

  • Bartkowiak D, Bottke D, Wiegel T. Radiotherapy in the management of prostate cancer after radical prostatectomy. Future Oncol. 2013 May;9(5):669-79.

Ausgewählte Publikationen 2012

  • Bottke D, Bartkowiak D, Schrader M, Wiegel T: Radiotherapy after radical prostatectomy: immediate or early delayed? Strahlenther Onkol. 2012 Dec;188(12):1096-1101.

  • Briganti A, Wiegel T, Joniau S, Cozzarini C, Bianchi M, Sun M, Tombal B, Haustermans K, Budiharto T, Hinkelbein W, Di Muzio N, Karakiewicz PI, Montorsi F, Van Poppel H: Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol. 2012 Sep;62(3):472-87.

  • Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87.
  • Budäus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T: Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012 Jan;61(1):112-27.

  • Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, Bartkowiak D, Hinkelbein W, Wiegel T: Salvage radiotherapy after prostatectomy - what is the best time to treat? Radiother Oncol. 2012 May;103(2):239-43.
  • Bartkowiak D, Humble N, Suhr P, Hagg J, Mair K, Polivka B, Schneider U, Bottke D, Wiegel T. Second cancer after radiotherapy, 1981-2007. Radiother Oncol. 2012 Oct;105(1):122-6.

Ausgewählte Publikationen

 

2011

 

  • Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011 Jan;59(1):61-71.
  • Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V; ESMO Guidelines Working Group: Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22 Suppl 6:vi45-9.
  • Siegmann A, Bottke D, Faehndrich J, Lohm G, Miller K, Bartkowiak D, Wiegel T, Hinkelbein W: Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival : Results of a retrospective study. Strahlenther. Onkol. 2011,187:467-72.
  • Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F: EAU Guidelines on Prostate Cancer. Part I: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Actas Urol Esp. 2011 Jul 12. [Epub ahead of print]
  • Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Actas Urol. Esp. 2011 Jul 12. [Epub ahead of print]
  • Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2011,59:572-83.

 

2010

    • Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease.
      Eur Urol. 2010 Oct 28.  [Epub ahead of print]
    • Wenz F, Martin T, Böhmer D, Martens S, Sedlmayer F, Wirth M, Miller K, Heidenreich A, Schrader M, Hinkelbein W, Wiegel T. The German S3 Guideline Prostate Cancer : Aspects for the Radiation Oncologist.
      Strahlenther Onkol. 2010;186:531-4
    • Kornmann M, Staib L, Wiegel T, Kreuser ED, Kron M, Baumann W, Henne-Bruns D, Link KH. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-a.
      Br J Cancer. 2010;103:1163-72.
    • Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
      J Clin Oncol. 2010;28:4199-206.
    • Welte B, Suhr P, Bottke D, Bartkowiak D, Dörr W, Trott KR, Wiegel T. Second Malignancies in High-Dose Areas of Previous Tumor Radiotherapy.
      Strahlenther Onkol. 2010;186:175-79.
      • Kilian HG, Kazda M, Király F, Kaufmann D, Kemkemer R, Bartkowiak D: On the structure-bounded growth processes in plant populations.
        Cell Biochem Biophys. 2010;57:87-100.
      • Bottke D, WiegelT: Radiotherapy and Prostate Cancer: Quo Vadis?
        Eur Urol. 2010;Suppl 9,394-400
          • Martin T, Wenz F, Böhmer D, Sedlmayer F, Hinkelbein W, Henkel TO, Miller K, Wiegel T: [Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy]
            Urologe A. 2010 Feb;49(2):216-20.
          • Böhmer D, Wenz F, Martin T, Sedlmayr F, Hinkelbein W, Wiegel T: [Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer]
            Urologe A. 2010 Feb;49(2):211-5.
          • Grimm MO, Thomas C, Fröhner M, Wiegel T, Heidenreich A, Thüroff JW, Wirth M: [Pelvic lymphadenectomy and radical prostatectomy. Recommendations of the German S3 guideline]
            Urologe A. 2010 Feb;49(2):206-10.
          • Welte B, Suhr P, Bottke D, Bartkowiak D, Dörr W, Trott KR, Wiegel T: Second malignancies in high-dose areas of previous tumor radiotherapy.
            Strahlenther Onkol. 2010 Mar;186(3):174-9.
          • Meisner J, Meyer A, Polivka B, Karstens JH, Bremer M: Outcome of moderately dosed radiosurgery for limited brain metastases. Report of a single-center experience.
            Strahlenther Onkol. 2010 Feb;186(2):76-81.

           

          2009

          • Reiter R, Deutschle T, Wiegel T, Riechelmann H, Bartkowiak D: Absence of inflammatory response from upper airway epithelial cells after X irradiation.
            Radiat Res. 2009 Mar;171(3):274-82.
          • Bottke D, de Reijke TM, Bartkowiak D, Wiegel T: Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer.
            Eur J Cancer. 2009 Sep;45 Suppl 1:148-57.
          • Bartkowiak D, Stempfhuber M, Wiegel T, Bottke D: Radiation- and chemoinduced multidrug resistance in colon carcinoma cells.
            Strahlenther Onkol. 2009 Dec;185(12):815-20.
          • Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
            J Clin Oncol. 2009 Jun 20;27(18):2924-30.
          • Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W:  Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
            Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1009-16.
          • Sautter-Bihl ML, Sedlmayer F, Wiegel T: Postoperative radiotherapy for advanced prostate cancer: improved local control translates into increased survival.
            Strahlenther Onkol. 2009 Aug;185(8):485-7.
          • de Reijke TM, Wiegel T: Treatment of local progression following radiotherapy.
            Eur J Cancer. 2009 Sep;45 Suppl 1:140-7.
          • Steinmann D, Schäfer C, van Oorschot B, Wypior HJ, Bruns F, Bölling T, Sehlen S, Hagg J, Bayerl A, Geinitz H, Hipp M, Vordermark D: Effects of radiotherapy for brain metastases on quality of life (QoL). Prospective pilot study of the DEGRO QoL working party.
            Strahlenther Onkol. 2009 Mar;185(3):190-7.

           

          2008

          • Bottke D, Koychev D, Busse A, Heufelder K, Wiegel T, Thiel E, Hinkelbein W, Keilholz U: Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines.
            Radiat Res. 2008 Jul;170(1):41-8.
          • Bottke D, Wiegel T: Postoperative adjuvant radiotherapy - standard of care?
            Front Radiat Ther Oncol. 2008;41:32-8.
          • Bottke D, Wiegel T: pT3R1 prostate cancer : Immediate or delayed radiotherapy after radical prostatectomy?
            Urologe A. 2008 Nov;47(11):1431-5.
          • Kreusel KM, Bechrakis NE, Wiegel T, Krause L, Foerster MH: Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer.
            Acta Ophthalmol. 2008 Aug;86(5):515-9.
          • Kilian HG, Bartkowiak D, Kaufmann D, Kemkemer R: The general growth logistics of cell populations.
            Cell Biochem Biophys. 2008;51(2-3):51-66.
          • Söhn M, Birkner M, Chi Y, Wang J, Di Y, Berger B, Alber M: Model-independent, multimodality deformable image registration by local matching of anatomical features and minimization of elastic energy.
            Med Phys. 2008 Mar;35(3):866-78.

           

          2007

          • Kreusel KM, Bechrakis NE, Krause L, Wiegel T, Foerster MH: Incidence and clinical characteristics of symptomatic choroidal metastasis from breast cancer.
            Acta Ophthalmol Scand. 2007 May;85(3):298-302.
          • Bottke D, Wiegel T, Kreienberg R, Kurzeder C, Sauer G: Stage IB endometrial cancer. Does lymphadenectomy replace adjuvant radiotherapy?
            Strahlenther Onkol. 2007 Nov;183(11):600-4.
          • Lohr F, Boda-Heggemann J, Wenz F, Wiegel T: Image-guided radiotherapy for prostate cancer.
            Aktuelle Urol. 2007 Sep;38(5):386-91; discussion 385.
          • Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE: Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.
            BJU Int. 2007 Oct;100(4):786-93.
          • Bottke D, Wiegel T: Adjuvant radiotherapy after radical prostatectomy: indications, results and side effects.
            Urol Int. 2007;78(3):193-7..
          • Bottke D, Wiegel T: Percutaneous radiotherapy for low-risk prostate cancer: options for 2007.
            World J Urol. 2007 Mar;25(1):53-7.
          • Bottke D, Bathe K, Wiegel T, Hinkelbein W: Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck.
            Strahlenther Onkol. 2007 Mar;183(3):128-32.
          • Bartkowiak D, Hipp PR, Mendonca MS, Röttinger EM. A radioprotective effect of imatinib (Gleevec) in human squamous carcinoma cells.
            Strahlenther Onkol. 2007 Aug;183(8):432-9.
          • Birkner M, Thorwarth D, Poser A, Ammazzalorso F, Alber M: Analysis of the rigid and deformable component of setup inaccuracies on portal images in head and neck radiotherapy.
            Phys Med Biol. 2007 Sep 21;52(18):5721-33.
          gepunktete blaue Linie 1000px breit